British/Dutch Study Discovers Role of ANG Gene Mutations in ALS-FTD
Researchers at the University of Bath in the United Kingdom and the University Medical Center Utrecht in the Netherlands have uncovered an association between an inherited genetic variant of the angiogenin (ANG) gene and ALS-FTD, according to a study published in The Journal of Pathology. It is now recognized that a pathogenic expansion of the…
Read MoreAFTD and ALLFTD Collaborate on Brain Donation Video
AFTD and ALLFTD have partnered to create a brief animated video that explains the brain donation process, as well as how it helps FTD researchers and families affected by FTD. Discussing brain donation can be difficult for families, so beginning the conversation early can provide family members with the time to consider options, share preferences,…
Read MoreDear HelpLine: Support for Familial and Genetic FTD
Dear HelpLine, My mom was recently diagnosed with FTD; my late uncle and grandmother had dementia, and I’m concerned that this may be genetic. Is there support for people facing uncertain genetic status? Most people diagnosed with FTD have a sporadic form of the disorder, meaning there is no apparent familial history of neurodegenerative disease.…
Read MoreAdvocate for Awareness: Working with Lawmakers to Highlight FTD
FTD advocates can help bring awareness to their communities by working with lawmakers to issue proclamations and resolutions designating a statewide FTD awareness week. But what are proclamations and resolutions, and how can advocates push for them? In this Advocacy Webinar, AFTD staff will explain the difference and share the steps that you can take…
Read MoreFTD: The Other Dementia
AFTD Ambassador Nanci Anderson will provide an overview of FTD, along with available resources available in the Twin Cities and from AFTD. Download this flyer to learn more.
Read MoreJuly 17, 2024 — FTD: The Other Dementia
AFTD Ambassador Nanci Anderson will provide an overview of FTD, along with available resources available in the Twin Cities and from AFTD. The event will take place on July 17, 2024, from 10:30 a.m. – 11:30 a.m. CT. It will be located at the Plymouth Community Center’s Education Wing (Classroom 1C), at 14800 34th Avenue…
Read MoreVesper Bio Completes Single Ascending Dose Stage of Its Clinical Trial for Potential Disease Modifying Treatment for FTD-GRN
Biotechnology company Vesper Bio announces it has completed the single ascending dose stage in its clinical trial of its potentially disease-modifying treatment for FTD-GRN. The goal of the single ascending dose stage was to determine how the body absorbs, distributes, and metabolizes the drug, as well as to monitor potential side effects. The study also…
Read MoreDelaware Passes Resolution Recognizing FTD Awareness Week 2024
Delaware became the third state to officially recognize FTD Awareness Week 2024 (September 22-29) after its Senate unanimously passed the resolution SR23 on June 27. State Senator Kyra Hoffner sponsored and introduced the resolution to the legislative chamber, citing the story of Jeanne Cestone, one of her constituents. Ms. Cestone, who was present for the…
Read MoreAdvocacy Update: Join AFTD in Advocating for FTD Awareness Week in All 50 States
This past May, AFTD staff and other FTD advocates traveled to New York and California to celebrate the successful passing of their respective resolutions that commemorate September 22-29 as FTD Awareness Week. Now, we need your help to support FTD Awareness Week in every state! What Is the Difference between a Proclamation and Resolution? Awareness…
Read MoreStudy Explores Racial Differences in Clinical Presentation of FTD Symptoms, Disease Severity
A study published in JAMA Neurology explores whether FTD symptoms present differently based on the race of the person diagnosed. Previous studies have sought to compare neuropsychiatric symptoms in Black/African American and White individuals — though, as the authors point out, this research has either been related to Alzheimer’s disease or was a part of…
Read More